Syninnova Laboratories Inc

SynInnova was established in 2008 to provide support for pharmaceutical, biotech, and academic research organizations engaged in drug discovery research programs. The company offers Ph.D. and M.S. level Full Time Equivalent (FTE) scientists, as well as Fee for Services (FFS) programs. The team has experience in a range of chemical synthesis areas and adheres to principles of quality, confidentiality, and timeliness. To address customers' needs for cost-effective and timely solutions, SynInnova has established a new research facility in the chemical hub of Hyderabad, India. Operations began on August 1, 2023, with over 40 research chemists, having access to analytical facilities, chiral synthesis, and separation. We offer Custom synthesis for early, mid-stage, New Chemical Entities (NCEs), and as well as advanced research chemicals that focus on various biological mechanisms, including inhibitors, agonists, antagonists, modulators, and blockers. SynInnova also synthesizes FDA-approved drugs and clinical trial compounds for use as reference materials, along with stable isotopically labelled compounds. The company supplies research chemicals that are challenging to synthesize or source efficiently and at competitive prices to assist life science research across multiple therapeutic fields. The compound libraries are designed to have drug-like properties against recognized target enzymes, applying published scaffolds in major therapeutic areas such as cancer, metabolic disorders, pain, and inflammatory diseases through traditional medicinal chemistry principles. Offered products include advanced intermediates and scaffolds like building blocks, novel amines, protected amines, unnatural amino acids, ketones, aldehydes, monocyclic, bicyclic, and tricyclic heterocycles containing up to three heteroatoms, isatoic anhydrides, boronic acids, boronic esters, peptides, glyco-peptides, carbohydrates, and chiral intermediates relevant to drug research.